Relay Therapeutics (RLAY) Net Equity Issued and Repurchased (2019 - 2024)
Relay Therapeutics (RLAY) posted quarterly Net Equity Issued and Repurchased of $218.2 million for Q3 2024, up 2221.28% year-over-year from $9.4 million in Q4 2023, and up 1118.99% quarter-over-quarter from $17.9 million in Q1 2024.
Relay Therapeutics (RLAY) Net Equity Issued and Repurchased (2019 - 2024) Analysis & Trends
Relay Therapeutics (RLAY) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $218.2 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Net Equity Issued and Repurchased rose 2221.28% year-over-year to $218.2 million; the TTM figure through Sep 2024 stood at $530.2 million (up 79.22% YoY), while the FY2024 annual figure was $17.9 million, down 40.92% from the prior year.
- Net Equity Issued and Repurchased grew to $218.2 million in Q3 2024 per RLAY's latest filing, from $17.9 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $284.7 million in Q3 2022 and bottomed at $56000.0 in Q4 2020.
- Historically, Net Equity Issued and Repurchased has averaged $38.4 million across 5 years, with a median of $892500.0 in 2021.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased surged 31463.19% — and 2023, when it sank 96.7%.
- Relay Therapeutics' Net Equity Issued and Repurchased stood at $56000.0 in 2020, then soared by 1080.36% to $661000.0 in 2021, then surged by 42971.1% to $284.7 million in 2022, then plunged by 96.7% to $9.4 million in 2023, then soared by 2221.28% to $218.2 million in 2024.
- Business Quant data shows RLAY's Net Equity Issued and Repurchased at $218.2 million in Q3 2024, $17.9 million in Q1 2024, and $9.4 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 218.20 Mn |
| Sep 30, 2024 | 218.20 Mn |
| Mar 31, 2024 | 17.90 Mn |
| Mar 31, 2024 | 17.90 Mn |
| Sep 30, 2023 | 9.40 Mn |
| Sep 30, 2023 | 9.40 Mn |
| Sep 30, 2022 | 284.70 Mn |
| Sep 30, 2022 | 284.70 Mn |
| Jun 30, 2022 | 859,000.00 |
| Jun 30, 2022 | 859,000.00 |
| Mar 31, 2022 | 883,000.00 |
| Mar 31, 2022 | 883,000.00 |
| Dec 31, 2021 | 661,000.00 |
| Dec 31, 2021 | 661,000.00 |
| Sep 30, 2021 | 902,000.00 |
| Sep 30, 2021 | 902,000.00 |
| Jun 30, 2021 | 1.12 Mn |
| Jun 30, 2021 | 1.12 Mn |
| Mar 31, 2021 | 2.06 Mn |
| Mar 31, 2021 | 2.06 Mn |